Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C

[1] Manns MP(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958-965

[2] McHutchison JG(2002)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-982

[3] Gordon SC(2004)Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-355

[4] Rustgi VK(2005)Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 636-641

[5] Shiffman M(2007)Race, insulin resistance and hepatic steatosis in chronic hepatitis C Hepatology 45 80-87

[6] Reindollar R(2005)Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 1437-1444

[7] Goodman ZD(2009)Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399-401

[8] Koury K(2009)IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100-1104

[9] Ling M(2009)Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105-1109

[10] Albrecht JK(2007)Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1 Hepatology 46 982-990

[1] Manns MP(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958-965

[2] McHutchison JG(2002)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-982

[3] Gordon SC(2004)Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-355

[4] Rustgi VK(2005)Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 636-641

[5] Shiffman M(2007)Race, insulin resistance and hepatic steatosis in chronic hepatitis C Hepatology 45 80-87

[6] Reindollar R(2005)Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 1437-1444

[7] Goodman ZD(2009)Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399-401

[8] Koury K(2009)IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100-1104

[9] Ling M(2009)Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105-1109

[10] Albrecht JK(2007)Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1 Hepatology 46 982-990